Abstract
Existing measures for functional assessment do not adequately address the relationship between cognitive impairment and function. The Schizophrenia Outcomes Functioning Interview (SOFI) was developed to measure community functioning related to cognitive impairment and psychopathology. Following review of existing measures and discussion with experts, caregivers, and patients, content was generated for four domains: 1) living situation; 2) IADLs; 3) productive activities; and 4) social functioning. The final SOFI was constructed with items informing domain scores, and an interviewer-completed global rating for each domain. Psychometric characteristics of the SOFI were evaluated in a sample of 104 community residing patients with schizophrenia and their informants. Test-retest reliability was evaluated in a sub-sample of patient-informant dyads using ICC; all values were > 0.70 for both patient-interviews (SOFI-P) and informant-interviews (SOFI-I). Inter-rater reliability ICCs ranged from 0.50 to 0.79 on a different sub-sample. The SOFI demonstrated adequate construct validity based on correlations with the PSP (range 0.58 to 0.76; p < 0.0001) and the QLS (p < 0.001). Some correlations between SOFI and PETiT scores were low to moderate (p < 0.05). Discriminant validity was supported based on SOFI score comparisons for patient groups based on PANSS and BACS scores (p < 0.05); SOFI scores differed between borderline and moderately ill patients as measured by the CGI-S (p < 0.05). The SOFI expands on existing measures and more comprehensively captures functioning of patients in the real world than other performance-based (proxy) measures. The SOFI has good evidence supporting reliability and construct validity, and may be a useful measure of functional outcomes in schizophrenia.
Original language | English |
---|---|
Pages (from-to) | 275-285 |
Number of pages | 11 |
Journal | Schizophrenia Research |
Volume | 107 |
Issue number | 2-3 |
DOIs | |
State | Published - Feb 2009 |
Externally published | Yes |
Bibliographical note
Funding Information:Drs. Kleinman, Revicki, and Frank are employed by United BioSource Corporation, recipient of a research contract from Eli Lilly to support this project. Drs. Zhao, Dube, Kinon, and Mohs are employees of Eli Lilly. Drs. Lieberman, Carpenter, Harvey, Green, and Keefe received advisory fees for meeting participation. The academic authors did not receive any additional funds for manuscript development. The authors had sole responsibility for manuscript preparation.
Funding
Drs. Kleinman, Revicki, and Frank are employed by United BioSource Corporation, recipient of a research contract from Eli Lilly to support this project. Drs. Zhao, Dube, Kinon, and Mohs are employees of Eli Lilly. Drs. Lieberman, Carpenter, Harvey, Green, and Keefe received advisory fees for meeting participation. The academic authors did not receive any additional funds for manuscript development. The authors had sole responsibility for manuscript preparation.
Funders | Funder number |
---|---|
Eli Lilly and Company |
Keywords
- Cognitive impairment
- Functioning
- Outcomes assessment
- Reliability
- Schizophrenia
- Validity